1st Apr 2021 07:05
1 April 2021
RTW Venture Fund Limited
(the "Company")
TOTAL VOTING RIGHTS
In accordance with DTR 5.6.1R as at 31 March 2021 the Company had 204,047,167 Ordinary Shares in issue, each with equal voting rights and no shares held in Treasury.
The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225-8885
J.P. Morgan Cazenove +44 (0) 20 7742 4000
William Simmonds
James Bouverat (Sales)
Barclays +44 (0) 20 7623 2323
Tom Swerling
Andrew Tusa
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
Related Shares:
Rtw Biotech